Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Gulf Achievement of Cholesterol Targets in Out-Patients Study (GULF ACTION): Design, Rationale, and Preliminary Results

Author(s): Hanan B Albackr, Khalid Al Waili, Wael Almahmeed, Mohammad Al Jarallah, Mohammad I Amin, Khalid Alrasadi, Mohammed A. Batais, Turky H. Almigbal, Ali Youssef, Mohammad Alghamdi, Mohammad Al Shehri, Islam Ahmad, Riham A. ElToukhy, Naji Kholaif, Abdulhalim J. Kinsara, Manal Al-Kindi, Nooshin Barzargani, Magdy Hassan, Shamsa Al Suwaidi, Rajesh Rajan, Hani Altaradi and Khalid F Alhabib*

Volume 21, Issue 4, 2023

Published on: 18 August, 2023

Page: [285 - 292] Pages: 8

DOI: 10.2174/1570161121666230710145604

Price: $65

conference banner
Abstract

Aim: To assess the current dyslipidemia management in the Arabian Gulf region by describing the demographics, study design, and preliminary results of out-patients who achieved low-density lipoprotein cholesterol (LDL-C) goals at the time of the survey.

Background: The Arabian Gulf population is at high risk for atherosclerotic cardiovascular disease at younger ages. There is no up-to-date study regarding dyslipidemia management in this region, especially given the recent guideline-recommended LDL-C targets.

Objective: Up-to-date comprehensive assessment of the current dyslipidemia management in the Arabian Gulf region, particularly in view of the recent evidence of the additive beneficial effects of ezetimibe and proprotein convertase subtilisin/kexin-9 (PCSK-9) inhibitors on LDL-C levels and cardiovascular outcomes.

Methods: The Gulf Achievement of Cholesterol Targets in Out-Patients (GULF ACTION) is an ongoing national observational longitudinal registry of 3000 patients. In this study, adults ≥18 years on lipidlowering drugs for over three months from out-patients of five Gulf countries were enrolled between January 2020 and May 2022 with planned six-month and one-year follow-ups.

Results: Of the 1015 patients enrolled, 71% were male, aged 57.9±12 years. In addition, 68% had atherosclerotic cardiovascular disease (ASCVD), 25% of these patients achieved the LDL-C target, and 26% of the cohort were treated using combined lipid-lowering drugs, including statins.

Conclusion: The preliminary results of this cohort revealed that only one-fourth of ASCVD patients achieved LDL-C targets. Therefore, GULF ACTION shall improve our understanding of current dyslipidemia management and “guideline gaps” in the Arabian Gulf region.

« Previous
Graphical Abstract

[1]
Aljefree N, Ahmed F. Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf region: A systematic review. Adv Public Health 2015; 2015: 1-23.
[http://dx.doi.org/10.1155/2015/235101]
[2]
Al-Rasadi K, Al-Zakwani I, Al Mahmeed W, et al. Therapeutic lipid target achievements among high and highest risk patients: Results from the CEPHEUS study in the Arabian Gulf. Curr Med Res Opin 2014; 30(12): 2429-35.
[http://dx.doi.org/10.1185/03007995.2014.965774] [PMID: 25222765]
[3]
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol 2019; 74(10): e177-232.
[http://dx.doi.org/10.1016/j.jacc.2019.03.010] [PMID: 30894318]
[4]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[5]
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[6]
Chacko M, Sarma PS, Harikrishnan S, Zachariah G, Jeemon P. Family history of cardiovascular disease and risk of premature coronary heart disease: A matched case-control study. Wellcome Open Res 2020; 5: 70.
[http://dx.doi.org/10.12688/wellcomeopenres.15829.2] [PMID: 32518841]
[7]
Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2011; 2013(3): 19-62.
[8]
Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: A meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006; 17(6): 631-6.
[http://dx.doi.org/10.1097/MOL.0b013e32800ff750] [PMID: 17095907]
[9]
Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48(3): 438-45.
[http://dx.doi.org/10.1016/j.jacc.2006.04.070] [PMID: 16875966]
[10]
Costa J, Borges M, David C, Carneiro AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Metaanalysis of randomised controlled trials. BMJ 2006; 332(7550): 1115-24.
[http://dx.doi.org/10.1136/bmj.38793.468449.AE] [PMID: 16585050]
[11]
Zubaid M, Rashed WA, Almahmeed W, et al. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol 2009; 64(4): 439-46.
[http://dx.doi.org/10.2143/AC.64.4.2041607] [PMID: 19725435]
[12]
Alhabib KF, Kinsara AJ, Alghamdi S, et al. The first survey of the Saudi Acute Myocardial Infarction Registry Program: Main results and long-term outcomes (STARS-1 Program). PLoS One 2019; 14(5): e0216551.
[http://dx.doi.org/10.1371/journal.pone.0216551] [PMID: 31112586]
[13]
Gehani AA, Al-Hinai AT, Zubaid M, et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: The INTERHEART Middle East study. Eur J Prev Cardiol 2014; 21(4): 400-10.
[http://dx.doi.org/10.1177/2047487312465525] [PMID: 23125402]
[14]
Alhabib KF, Al-Rasadi K, Almigbal TH, et al. Familial hypercholesterolemia in the Arabian gulf region: Clinical results of the gulf FH registry. PLoS One 2021; 16(6): e0251560.
[http://dx.doi.org/10.1371/journal.pone.0251560] [PMID: 34086694]
[15]
Ramahi TM. Cardiovascular disease in the Asia Middle East region: Global trends and local implications. Asia Pac J Public Health 2010; 22(3_suppl)(Suppl.): 83S-9S.
[http://dx.doi.org/10.1177/1010539510373034] [PMID: 20566538]
[16]
Turk-Adawi K, Sarrafzadegan N, Fadhil I, et al. Cardiovascular disease in the Eastern Mediterranean region: Epidemiology and risk factor burden. Nat Rev Cardiol 2018; 15(2): 106-19.
[http://dx.doi.org/10.1038/nrcardio.2017.138] [PMID: 28933782]
[17]
Alhabib KF, Batais MA, Almigbal TH, et al. Demographic, behavioral, and cardiovascular disease risk factors in the Saudi population: Results from the Prospective Urban Rural Epidemiology study (PURE-Saudi). BMC Public Health 2020; 20(1): 1213.
[http://dx.doi.org/10.1186/s12889-020-09298-w] [PMID: 32770968]
[18]
Al Sifri SN, Almahmeed W, Azar S, et al. Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One 2014; 9(1): e84350.
[http://dx.doi.org/10.1371/journal.pone.0084350] [PMID: 24400085]
[19]
Arafah M, Al-Hinai AT, Mahmeed WA, et al. Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: Results from the CEPHEUS study in Arabian Gulf countries. Angiology 2014; 65(10): 919-26.
[http://dx.doi.org/10.1177/0003319713512414] [PMID: 24301426]
[20]
Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: Cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17(5): 530-40.
[http://dx.doi.org/10.1097/HJR.0b013e3283383f30] [PMID: 20577089]
[21]
Ray KK, Molemans B, Schoonen WM, et al. EU-Wi de cross-section al observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study. Eur J Prev Cardiol 2021; 28(11): 1279-89.
[http://dx.doi.org/10.1093/eurjpc/zwaa047] [PMID: 33580789]
[22]
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37(39): 2999-3058.
[http://dx.doi.org/10.1093/eurheartj/ehw272] [PMID: 27567407]
[23]
Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg Health Eur 2023; 29: 100624.
[http://dx.doi.org/10.1016/j.lanepe.2023.100624] [PMID: 37090089]
[24]
Grundy SM, Arai H, Barter P, et al. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. J Clin Lipidol 2014; 8(1): 29-60.
[http://dx.doi.org/10.1016/j.jacl.2013.12.005] [PMID: 24528685]
[25]
Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018; 25(10): 1087-94.
[http://dx.doi.org/10.1177/2047487318777079] [PMID: 29771156]
[26]
Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res 2019; 124(2): 328-50.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.312782] [PMID: 30653440]
[27]
Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J 2022; 43(8): 830-3.
[http://dx.doi.org/10.1093/eurheartj/ehab718] [PMID: 34636884]
[28]
Ray KK. Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care. Eur Heart J 2021; 42(3): 253-6.
[http://dx.doi.org/10.1093/eurheartj/ehaa1008] [PMID: 33454778]
[29]
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372(25): 2387-97.
[http://dx.doi.org/10.1056/NEJMoa1410489] [PMID: 26039521]
[30]
Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial. Lancet 2022; 400(10349): 380-90.
[http://dx.doi.org/10.1016/S0140-6736(22)00916-3] [PMID: 35863366]
[31]
Bardolia C, Amin NS, Turgeon J. Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol. Front Cardiovasc Med 2021; 8: 789931.
[http://dx.doi.org/10.3389/fcvm.2021.789931] [PMID: 34869702]
[32]
Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017; 9(2): 76-91.
[http://dx.doi.org/10.4330/wjc.v9.i2.76] [PMID: 28289523]
[33]
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020; 382(16): 1507-19.
[http://dx.doi.org/10.1056/NEJMoa1912387] [PMID: 32187462]
[34]
Nishikido T. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovasc Diabetol 2023; 22(1): 20.
[http://dx.doi.org/10.1186/s12933-023-01752-4] [PMID: 36717882]
[35]
Brandts J, Ray KK. Clinical implications and outcomes of the ORION Phase III trials. Future Cardiol 2021; 17(5): 769-77.
[http://dx.doi.org/10.2217/fca-2020-0150] [PMID: 33345605]
[36]
Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: A patient-level analysis of phase III trials. Eur Heart J 2023; 44(2): 129-38.
[http://dx.doi.org/10.1093/eurheartj/ehac594] [PMID: 36331326]
[37]
Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019; 380(11): 1022-32.
[http://dx.doi.org/10.1056/NEJMoa1803917] [PMID: 30865796]
[38]
Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs 2017; 26(2): 251-9.
[http://dx.doi.org/10.1080/13543784.2017.1280458] [PMID: 28064554]
[39]
Banach M, Penson PE, Farnier M, et al. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Prog Cardiovasc Dis 2023; S0033-0620(23): 00026-9.
[40]
Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 388(15): 1353-64.
[http://dx.doi.org/10.1056/NEJMoa2215024] [PMID: 36876740]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy